Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer

Cancer Chemotherapy and Pharmacology
Lian JiangDan-feng Wang

Abstract

This phase II study is performed to evaluate the safety, efficacy and tolerability of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer (NSCLC). All patients were treated with the combination of docetaxel 35 mg/m(2) by IV infusion over 30-60 min weekly, on days 1, 8, and 15, for 3 weeks followed by 1 week of rest, with intravenous carboplatin (AUC 6) administered immediately afterward on day 1. Cycles were repeated every 28 days. Forty-seven (95.9%) of the 49 patients were assessable for response, one case of complete response and 17 cases of partial response were confirmed, giving an overall response rate of 36.7% (95% CI 23.2-50.2%). The median time to progression and overall survival (OS) for all patients were 5.2 months (95% CI 4.1-6.3 months) and 10.4 months (95% CI 7.3-13.5 months), respectively. The estimate of OS at 12 months was 37.6% (95% CI 24.0-51.2%). The most severe hematologic adverse event was anemia, which occurred with grade 3/4 intensity in 7 (14.9%) patients. Neutropenia occurred with grade 3 intensity in 4 (8.5%) patients. However, no grade 4 neutropenia was observed. Grade 3 nausea/vomiting, diarrhea, asthenia, nail changes, and skin reaction were observed in 6...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F V FossellaB Glisson
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A FrancisR T Heelan
Jun 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F V FossellaS Benner
May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H KunitohT Taguchi
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J D HainsworthF A Greco
Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BriasoulisN Pavlidis
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R GandaraC Belani
Aug 15, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C P BelaniJ D Luketich
Jun 8, 2001·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·K ZarogoulidisD Patakas
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J MillwardJ F Bishop
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frank FossellaChandra P Belani
Oct 29, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E EstebanUNKNOWN Grupo Oncológico del Norte de España
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y OheY Nishiwaki
Feb 26, 2004·Seminars in Oncology·Sakkaraiappan Ramalingam, Chandra P Belani
Aug 25, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katsuyuki HottaMitsune Tanimoto
Dec 24, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CampsUNKNOWN Spanish Lung Cancer Group
Jan 24, 2007·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Rogerio LilenbaumHongyan Du
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Osamu IshimotoToshihiro Nukiwa
Jun 7, 2007·Journal of the National Cancer Institute·Andrea ArdizzoniUNKNOWN CISCA (CISplatin versus CArboplatin) Meta-analysis Group

❮ Previous
Next ❯

Citations

Oct 19, 2011·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·José Rodrigues-PereiraMauro Orlando

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.